About: Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
Creator	Jiang, Shibo Lu, Lu Xia, Shuai Hua, Chen Li, Weihua Wang, Cong
source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) has continuously posed a threat to public health worldwide, yet no therapeutics or vaccines are currently available to prevent or treat MERS-CoV infection. We previously identified a fusion inhibitory peptide (HR2P-M2) targeting the MERS-CoV S2 protein HR1 domain and a highly potent neutralizing monoclonal antibody (m336) specific to the S1 spike protein receptor-binding domain (RBD). However, m336 was found to have reduced efficacy against MERS-CoV strains with mutations in RBD, and HR2P-M2 showed low potency, thus limiting the clinical application of each when administered separately. However, we herein report that the combination of m336 and HR2P-M2 exhibited potent synergism in inhibiting MERS-CoV S protein-mediated cell–cell fusion and infection by MERS-CoV pseudoviruses with or without mutations in the RBD, resulting in the enhancement of antiviral activity in contrast to either one administered alone. Thus, this combinatorial strategy could be used in clinics for the urgent treatment of MERS-CoV-infected patients.
has issue date	2019-01-06(xsd:dateTime)
bibo:doi	10.3390/v11010031
bibo:pmid	30621343
has license	cc-by
sha1sum (hex)	cffa9b1def2d5c6d7bae6fb1ea9fa07948885c05
schema:url	https://doi.org/10.3390/v11010031
resource representing a document's title	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
has PubMed Central identifier	PMC6356712
has PubMed identifier	30621343
schema:publication	Viruses
resource representing a document's body	covid:cffa9b1def2d5c6d7bae6fb1ea9fa07948885c05#body_text
is schema:about of	named entity 'PREVIOUSLY' named entity 'MUTATIONS' named entity 'COMBINATION' named entity 'TREAT' named entity 'SYNERGISM' named entity 'OF EACH' named entity 'CLINICAL APPLICATION' named entity 'CELL-CELL FUSION' named entity 'MEDIATED' named entity 'IDENTIFIED' named entity 'CONTRAST' named entity 'INFECTION' named entity 'MONOCLONAL ANTIBODY' named entity 'LOW' named entity 'POTENCY' named entity 'FOUND' named entity 'WORLDWIDE' named entity 'TREATMENT' named entity 'FUSION' named entity 'NEUTRALIZING ANTIBODY' named entity 'TARGETING' named entity 'PROTEIN ' named entity 'MUTATIONS' named entity 'CLINICS' named entity 'INFECTED' named entity 'ANTIVIRAL ACTIVITY' named entity 'EITHER' named entity 'STRATEGY' named entity 'EFFICACY' named entity 'LIMITING' named entity 'HAVE' named entity 'SPECIFIC' named entity 'SPIKE PROTEIN' named entity 'DOMAIN' named entity 'RESULTING IN' named entity 'PEPTIDE' named entity 'VACCINES' named entity 'CURRENTLY' named entity 'PROTEIN RECEPTOR' named entity 'RBD' named entity 'THERAPEUTICS' named entity 'COULD BE' named entity 'BINDING' named entity 'SYNERGISM' named entity 'HR1 DOMAIN' named entity 'SPECIFIC' named entity 'DOMAIN' named entity 'PEPTIDE' named entity 'PROTEIN RECEPTOR' named entity 'MERS-COV' named entity 'INHIBITORY' named entity 'PUBLIC HEALTH' named entity 'REDUCED' named entity 'USED' named entity 'HR1 DOMAIN' named entity 'STRAINS' named entity 'MERS-COV S PROTEIN' named entity 'FUSION' named entity 'PROTEIN ' named entity 'HIGHLY' named entity 'TARGETING' named entity 'THREAT' named entity 'TO PREVENT' named entity 'INHIBITING' named entity 'URGENT' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'RBD' named entity 'COMBINING' named entity 'PATIENTS' named entity 'INHIBITORY' named entity 'BINDING' named entity 'AVAILABLE' named entity 'ADMINISTERED' named entity 'REPORT' named entity 'ENHANCEMENT' covid:arg/cffa9b1def2d5c6d7bae6fb1ea9fa07948885c05

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software